% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{HtterKrnke:128816,
      author       = {M.-L. Hütter-Krönke and A. Benner$^*$ and K. Döhner and
                      J. Krauter and D. Weber and M. Moessner and C.-H. Köhne and
                      H. A. Horst and I. G. H. Schmidt-Wolf and M. Rummel and K.
                      Götze and E. Koller and A. L. Petzer and H. Salwender and
                      W. Fiedler and H. Kirchen and D. Haase and S. Kremers and M.
                      Theobald and A. C. Matzdorff and A. Ganser and H. Döhner
                      and R. F. Schlenk},
      title        = {{S}alvage therapy with high-dose cytarabine and
                      mitoxantrone in combination with all-trans retinoic acid and
                      gemtuzumab ozogamicin in acute myeloid leukemia refractory
                      to first induction therapy.},
      journal      = {Haematologica},
      volume       = {101},
      number       = {7},
      issn         = {1592-8721},
      address      = {Pavia},
      publisher    = {Ferrata Storti Foundation},
      reportid     = {DKFZ-2017-04829},
      pages        = {839 - 845},
      year         = {2016},
      abstract     = {Outcome of patients with primary refractory acute myeloid
                      leukemia remains unsatisfactory. We conducted a prospective
                      phase II clinical trial with gemtuzumab ozogamicin (3
                      mg/m(2) intravenously on day 1), all-trans retinoic acid (45
                      mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days
                      7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on
                      days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days
                      2-3) in 93 patients aged 18-60 years refractory to one cycle
                      of induction therapy. Primary end point of the study was
                      response to therapy; secondary end points included
                      evaluation of toxicities, in particular, rate of sinusoidal
                      obstruction syndrome after allogeneic hematopoietic cell
                      transplantation. Complete remission or complete remission
                      with incomplete blood count recovery was achieved in 47
                      $(51\%)$ and partial remission in 10 $(11\%)$ patients
                      resulting in an overall response rate of $61.5\%;$ 33
                      $(35.5\%)$ patients had refractory disease and 3 patients
                      $(3\%)$ died. Allogeneic hematopoietic cell transplantation
                      was performed in 71 $(76\%)$ patients; 6 of the 71 $(8.5\%)$
                      patients developed moderate or severe sinusoidal obstruction
                      syndrome after transplantation. Four-year overall survival
                      rate was $32\%$ $(95\%$ confidence interval $24\%-43\%).$
                      Patients responding to salvage therapy and undergoing
                      allogeneic hematopoietic cell transplantation (n=51) had a
                      4-year survival rate of $49\%$ $(95\%$ confidence intervaI
                      $37\%-64\%).$ Patients with fms-like tyrosine kinase
                      internal tandem duplication positive acute myeloid leukemia
                      had a poor outcome despite transplantation. In conclusion,
                      the described regimen is an effective and tolerable salvage
                      therapy for patients who are primary refractory to one cycle
                      of conventional intensive induction therapy.
                      (clinicaltrials.gov identifier: 00143975).},
      keywords     = {Aminoglycosides (NLM Chemicals) / Antibodies, Monoclonal,
                      Humanized (NLM Chemicals) / Cytarabine (NLM Chemicals) /
                      Tretinoin (NLM Chemicals) / gemtuzumab (NLM Chemicals) /
                      Mitoxantrone (NLM Chemicals)},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27036160},
      pmc          = {pmc:PMC5004463},
      doi          = {10.3324/haematol.2015.141622},
      url          = {https://inrepo02.dkfz.de/record/128816},
}